|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 2 | Age and geochemistry of Early Ordovician A-type granites in the Northeastern Songnen Block,NE China显示文摘Early Ordovician A-type granites in the northeastern(NE) Songnen Block NE China were studied to better understand the geodynamic settings in this region.This research presents new zircon U–Pb ages and wholerock geochemical data for the Early Ordovician granites in the NE Songnen Block. Zircon U–Pb dating indicates that the granite in the Cuibei, Hongxing, and Meixi areas in the NE Songnen Block formed in the Early Ordovician with ages of 471–479 Ma. The granites show geochemical characteristics of high SiO2 and K2 O compositions and low FeOT, MgO, CaO, and P2 O5 compositions. They belong to a high K calc-alkaline series and display a weak peraluminous featurPe with A/CNK values of 0.98–1.14. The rocks have aREE composition of 249.98–423.94 ppm,and are enriched in LREE with(La/Yb)Nvalues of2.87–9.87, and display obvious Eu anomalies(d Eu =0.01–0.29). Trace elements of the studied granites are characterized by enrichment in Rb, Th, U, Pb, Hf, and Sm,and depletion of Ba, Nb, Ta, and Sr. They display geochemical features of high Zr +Y + Nb+Ce values(324–795 ppm) and Ga/Al ratios consistent with A-type granites. Based on particular geochemical features, such as high Rb/Nb(7.98–24.19) and Y/Nb(1.07–3.43), the studied A-type granites can be further classified as an A2-type subgroup. This research indicates that the Early Ordovician A-type granites were formed by the partial melting of ancient crust in an extensional setting. Lower Sr/Y and(Ho/Yb)Nratios indicate that plagioclase and amphibole are residual in the source, and garnet is absent, implying that the magma was generated at low levels of pressure. By contrast, the contemporaneous granites in the SE Xing'an Block suggest a subduction-related tectonic setting, and its adakitic property indicates a thickened continental crust.We suggest that the Paleo-Asian Ocean plate between the Xing'an and Songnen blocks subducted northward during the Early Ordovician. Meanwhile, the NE Songnen Block was exposed to a passive continental margin tectonic setting. | Changzhou Deng Deyou Sun Guangyi Sun Changlu Lv Zhen Qin Xianquan Ping Guanghui Li | 2018 | Acta Geochimica2018，37，6： | 1 |
| 3 | Status of transjugular intrahepatic portosystemic shunt for portal hypertension in China:A national survey analysis显示文摘Aim:The transjugular intrahepatic portosystemic shunt(TIPS)procedure has been performed in China for 30 years,but our understanding of the status and difficulties associated with the use of TIPS for portal hypertension is incomplete.This study aims to investigate the current situation of the use of TIPS for portal hypertension,which should aid the development of TIPS in China.Methods:This study involved a questionnaire survey,initiated by the China Portal Hypertension Alliance(CHESS)to investigate the use of TIPS for portal hypertension in China.Questionnaires were released on the Internet between August 16,2022 and September 16,2022.Detailed information was collected from 545 hospitals contracted by the CHESS in China,which performed TIPS surgery in 2021.Results:The 545 hospitals covers the majority of hospitals in China that conduct TIPS intervention.In the survey,a total of 13,527 TIPS interventions were carried out with 94.1%(498/545)of them had a system of routine follow‐up after TIPS.The majority(42.6%[232/545])believed that the main indication of TIPS was the control of acute bleeding.Overall,48.1%(262/545)carried out early or pre‐emptive TIPS,53.0%(289/545)carried out TIPS for cavernous transformation of the portal vein,and 81.0%(441/545)chose routine embolization of collateral circulation during operation.Most used coils(97.0%[475/490])and biological glue(72.0%[353/490])as embolic materials,and 78.5%(428/545)routinely performed intraoperative portal pressure gradient measurements.When selecting TIPS stents,57.1%(311/545)chose viator‐specific stents,and 57.2%(312/545)chose conventional anticoagulation after TIPS.Conventional anticoagulation after TIPS is over a time interval of 3–6 months(55.4%[173/312]).The limitation of TIPS surgery is mainly its cost(72.3%[394/545])and insufficient understanding of the procedure by doctors in other related departments(77.4%[422/545]).Most of the hospital teams accept the use of domestic instruments in TIPS surgery(92.7%[505/545]).Conclusions:This survey shows that TIPS is an essential part of the treatment of portal hypertension in China.TIPS is widely used in Chinese patients with portal hypertension,and this survey presents a more comprehensive picture of the options and difficulties encountered in the implementation of TIPS.In the future,it is necessary to promote TIPS technology and further standardize surgical indications,routine operations,and instrument application. | Haibo Shao Xinwei Han Jianbo Zhao Junhui Sun Zhuting Fang Bin Xiong Xiaoli Zhu Weixin Ren Min Yuan Shiping Yu Meng Niu Weifu Lv Xueqiang Zhang Chunqing Zhang Lei Li Xuefeng Luo Yusheng Song Yilong Ma Tong Dang Hua Xiang Yun Jin Hui Xue Guiyun Jin Xiao Li Jiarui Li Shi Zhou Changlu Yu Song He Lei Yu Hongmei Zu Jun Ma Yanming Lei Ke Xu Xiaolong Qi | 2023 | Portal Hypertension & Cirrhosis2023，2，1： | 0 |
| 4 | Zero-pole cancellation for identity-based aggregators:a constant-size designated verifier-set signature显示文摘In this paper we present a designated verifier-set signature(DVSS),in which the signer allows to designate many verifiers rather than one verifier,and each designated verifier can verify the validity of signature by himself.Our research starts from identity-based aggregator(IBA)that compresses a designated set of verifier’s identities to a constant-size random string in cryptographic space.The IBA is constructed by mapping the hash of verifier’s identity into zero or pole of a target curve,and extracting one curve’s point as the result of aggregation according to a specific secret.Considering the different types of target curves,these two IBAs are called as zeros-based aggregator and poles-based aggregator,respectively.Based on them,we propose a practical DVSS scheme constructed from the zero-pole cancellation method which can eliminate the same elements between zeros-based aggregator and poles-based aggregator.Due to this design,our DVSS scheme has some distinct advantages:(1)the signature supporting arbitrary dynamic verifiers extracted from a large number of users;and(2)the signature with short and constant length.We rigorously prove that our DVSS scheme satisfies the security properties:correctness,consistency,unforgeability and exclusivity.This is a preview of subscription content,log in to check access. | E CHEN Yan ZHU Changlu LIN Kewei LV | 2020 | Frontiers of Computer Science2020，14，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员